Prognostic value of perineural invasion in ypⅠ-Ⅱ rectal cancer patients who received neoadjuvant radiotherapy

doi:10.19401/j.cnki.1007-3639.2022.12.011

Abstract

Abstract:

Background and purpose: Perineural invasion is a prognostic factor in colorectal cancer. It is unclear whether perineural invasion is a prognostic factor in in node-negative (ypⅠ-Ⅱ) rectal cancer patients who received neoadjuvant radiotherapy because there may be varying degrees of tumor regression. This study aimed to investigate prognostic value of perineural invasion in node-negative rectal cancer patients who received neoadjuvant radiotherapy. Methods: A total of 5 222 patients who received neoadjuvant radiotherapy and were diagnosed with stage ypⅠ-Ⅱ rectal cancer from the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2018 were identified and clinicopathological features and cancer-specific survival outcomes were retrospectively analyzed. Chi-square analysis was used to compare clinicopathological features between two groups. Kaplan-Meier survival analysis and the log-rank test were used to estimate the 5-year cancer-specific survival. Multivariable Cox regression analyses were used to identify the independent prognostic factor. Results: Compared with patients without perineural invasion, patients with perineural invasion were more likely to be black, have elevated carcinoembryonic antigen (CEA), stage Ⅱ disease, tumor<5 cm and poorer differentiated tumors (P<0.05). Patients without perineural invasion had superior cancer-specific survival than those with perineural invasion (5-years survival rate: 85.3% vs 68.9%). The survival difference was more evident in patients with stage ypⅡ cancer. Multivariable Cox regression analyses demonstrated that perineural invasion was an independent prognostic factor in node-negative rectal cancer patients who received neoadjuvant radiotherapy. Conclusion: Perineural invasion is associated with oncological outcomes of node-negative rectal cancer patients who received neoadjuvant radiotherapy, thus it could serve as a prognostic factor in these patients.

Key words: Perineural invasion, Rectal cancer, Neoadjuvant radiotherapy, Node-negative, Prognostic factor

CLC Number:

R735.3+7

WANG Jun, HE Ping. Prognostic value of perineural invasion in ypⅠ-Ⅱ rectal cancer patients who received neoadjuvant radiotherapy[J]. China Oncology, 2022, 32(12): 1229-1234.

Figures/Tables 5

Tab. 1

Fig. 1

Fig. 2

Fig. 3

Tab. 2

References 9

[1]	SAUER R, BECKER H, HOHENBERGER W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med, 2004, 351(17): 1731-1740. doi: 10.1056/NEJMoa040694
[2]	HUH J W, LEE J H, KIM H R. Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer[J]. Arch Surg, 2012, 147(4): 366-372. doi: 10.1001/archsurg.2012.35 pmid: 22508783
[3]	ALOTAIBI A M, LEE J L, KIM J, et al. Prognostic and oncologic significance of perineural invasion in sporadic colorectal cancer[J]. Ann Surg Oncol, 2017, 24(6): 1626-1634. doi: 10.1245/s10434-016-5748-4 pmid: 28070726
[4]	CAO Y H, DENG S H, YAN L Z, et al. Perineural invasion is associated with poor prognosis of colorectal cancer: a retrospective cohort study[J]. Int J Colorectal Dis, 2020, 35(6): 1067-1075. doi: 10.1007/s00384-020-03566-2 pmid: 32179991
[5]	CIENFUEGOS J A, MARTÍNEZ P, BAIXAULI J, et al. Perineural invasion is a major prognostic and predictive factor of response to adjuvant chemotherapy in stage Ⅰ-Ⅱ colon cancer[J]. Ann Surg Oncol, 2017, 24(4): 1077-1084. doi: 10.1245/s10434-016-5561-0
[6]	DOLL K M, RADEMAKER A, SOSA J A. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database[J]. JAMA Surg, 2018, 153(6): 588-589. doi: 10.1001/jamasurg.2018.0501 pmid: 29617544
[7]	SKANCKE M, ARNOTT S M, AMDUR R L, et al. Lymphovascular invasion and perineural invasion negatively impact overall survival for stage Ⅱ adenocarcinoma of the colon[J]. Dis Colon Rectum, 2019, 62(2): 181-188. doi: 10.1097/DCR.0000000000001258
[8]	TU J H, YAO Z X, WU W Q, et al. Perineural invasion is a strong prognostic factor but not a predictive factor of response to adjuvant chemotherapy in node-negative colon cancer[J]. Front Oncol, 2021, 11: 663154.
[9]	TU J H, YAO Z X, WU W Q, et al. Perineural invasion is a strong prognostic factor but not a predictive factor of response to adjuvant chemotherapy in node-negative colon cancer[J]. Front Oncol, 2021, 11: 663154.

Variable	Positive (n=329)	Negative (n=4 893)	P value	Variable	Positive (n=329)	Negative (n=4 893)	P value
Age/year	60.5±11.8	61.2±11.8	0.261	Tumor size/cm			0.004
Gender			0.397	<5	194 (59.0)	2 491 (50.9)
Male	198 (60.2)	3 059 (62.5)		≥5	93 (28.3)	1 455 (29.7)
Female	131 (39.8)	1 834 (60.2)		Unknown	42 (12.8)	947 (19.4)
Race			0.002	Histological type			0.767
White	253 (76.9)	4 003 (81.8)		Adenocarcinoma	270 (82.1)	3 962 (81.0)
Black	44 (13.4)	386 (7.9)		Mucinous adenocarcinoma	16 (4.9)	224 (4.6)
Other	32 (9.7)	504 (10.3)		Signet ring carcinoma	2 (0.6)	18 (0.4)
Marital status			0.723	Unknown	41 (12.5)	689 (14.1)
Single/divorced	126 (38.3)	1 807 (36.9)		Grade			0.001
Married	191 (58.1)	2 867 (58.6)		Well	14 (4.3)	355 (7.3)
Unknown	12 (3.6)	219 (4.5)		Moderate	241 (73.3)	3 525 (72.0)
CEA level			<0.001	Poor	40 (12.2)	339 (6.9)
Normal	104 (31.6)	1 997 (40.8)		Undifferentiated	4 (1.2)	47 (1.0)
Elevated	118 (35.9)	1 291 (26.4)		Unknown	30 (9.1)	627 (12.8)
Unknown	107 (32.5)	1 605 (32.8)
Stage			<0.001
Ⅰ	30 (9.1)	1 186 (24.2)
Ⅱ	299 (90.9)	3 707 (75.8)

Variable	Univariate analysis		Multivariable analysis
Variable	HR (95% CI)	P value	HR (95% CI)	P value
Age	1.026 (1.020-1.032)	<0.001	1.027 (1.021-1.033)	<0.001
Gender
Male	Reference		Reference
Female	0.841 (0.731-0.967)	0.015	0.781 (0.677-0.901)	0.001
Race
White	Reference		-
Black	1.165 (0.928-1.463)	0.187
Others	0.802 (0.632-1.018)	0.070
Marital status
Single/divorced	Reference		Reference
Married	0.695 (0.606-0.797)	<0.001	0.679 (0.591-0.780)	<0.001
Unknown	-		-
CEA level
Normal	Reference		Reference
Elevated	1.585 (1.348-1.863)	<0.001	1.469 (1.248-1.728)	<0.001
Unknown	-
Stage
Ⅰ	Reference		Reference
Ⅱ	1.344 (1.136-1.591)	0.001	1.200 (1.011-1.426)	0.037
Tumor size/cm
<5	Reference		Reference
≥5	1.278 (1.100-1.484)	0.001	1.213 (1.043-1.411)	0.012
Unknown	-		-
Histological type
Adenocarcinoma	Reference		Reference
Mucinous adenocarcinoma	1.746 (1348-2.260).	<0.001	1.614 (1.245-2.093)	<0.001
Signet ring carcinoma	6.060 (3.421-10.734)	<0.001	5.651 (3.144-10.157)	<0.001
Unknown	-		-
Grade
Well	Reference		Reference
Moderate	1.024 (0.779-1.347)	0.865	1.030 (0.782-1.355)	0.835
Poor	1.711 (1.232-2.376)	0.001	1.482 (1.064-2.065)	0.020
Undifferentiated	2.325 (1.315-4.111)	0.004	2.247 (1.269-3.978)	0.005
Unknown	-		-
Perineural invasion
Negative	Reference		Reference
Positive	2.492 (2.042-3.042)	<0.001	2.454 (2.005-3.004)	<0.001

[1]	HUANG Haozhe, CHEN Hong, ZHENG Dezhong, CHEN Chao, WANG Ying, XU Lichao, WANG Yaohui, HE Xinhong, YANG Yuanyuan, LI Wentao. A CT-based radiomics nomogram for predicting local tumor progression of colorectal cancer lung metastases treated with radiofrequency ablation [J]. China Oncology, 2024, 34(9): 857-872.
[2]	WU Wen, ZHANG Ruoxin, WENG Junyong, MA Yanlei, CAI Guoxiang, LI Xinxiang, YANG Yongzhi. Exploring the prognostic value of positive lymph node ratio in stage Ⅲ colorectal cancer patients and establishing a predictive model [J]. China Oncology, 2024, 34(9): 873-880.
[3]	YAN Yan, ZHOU Liqing, XIA Jianhong, MA Tingting. TCF7 transcriptional activation of MACC1 regulates aerobic glycolysis and promotes oxaliplatin resistance in rectal cancer [J]. China Oncology, 2024, 34(8): 715-725.
[4]	GE Zuyin, SONG Kun, LIN Yunxiao, ZHONG Yeling, HAO Jingduo. The feasibility study of FCGBP and BIGH3 in circulating tumor cells as potential markers for colorectal cancer [J]. China Oncology, 2024, 34(8): 745-752.
[5]	WENG Junyong, YE Zilan, ZHANG Ruoxin, LIU Qi, LI Xinxiang. Exploring the guiding role of the number of adverse pathological features in risk stratification for recurrence of stage Ⅰ-Ⅲ colorectal cancer: a retrospective cohort study of 9 875 cases [J]. China Oncology, 2024, 34(6): 527-536.
[6]	ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang. Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients [J]. China Oncology, 2024, 34(5): 485-492.
[7]	LU Yue, LU Renquan, ZHANG Jie, ZHENG Hui. Application value of combined coagulation function indicators in monitoring hypercoagulable state of patients with colorectal cancer after chemotherapy [J]. China Oncology, 2024, 34(3): 278-285.
[8]	LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng. Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. China Oncology, 2024, 34(2): 191-200.
[9]	LI Jun, LU Tingwei, FANG Xuqian. Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer [J]. China Oncology, 2024, 34(11): 1061-1066.
[10]	WU Zhibai, XU Guiqin, ZHANG Li, YANG Zhaojuan, LIU Yun, JIAO Kun, CHEN Zehong, XU Chen, ZUO You, ZHENG Ningqian, YE Zhiqian, LIU Yongzhong. Mechanism study of KCMF1 promoting proliferation and NF-κB signaling transduction in colorectal cancer cells [J]. China Oncology, 2024, 34(11): 987-997.
[11]	CHU Yajuan, ZHANG Lei, LI Yunhai, LUO Weiming, ZHANG Jing, MO Xiaochen, MA Jinli. Exploring the attenuating effect of amifostine on neoadjuvant radiotherapy with concurrent use of irinotecan for locally advanced rectal cancer: a retrospective cohort study of 154 cases [J]. China Oncology, 2024, 34(10): 957-965.
[12]	ZHANG Shaohua, LI Zhening, WANG Wei, WEI Yifan, HONG Yonggang, HAO Liqiang. Research progress in the related treatment of KRAS mutant colorectal cancer [J]. China Oncology, 2024, 34(10): 979-986.
[13]	Colorectal Cancer Special Committee of Shanghai Anti-Cancer Association . Shanghai plan for early screening, diagnosis and treatment of colorectal cancer (2023 edition) [J]. China Oncology, 2024, 34(1): 13-66.
[14]	WU Han, XU Lei, WANG Miaomiao, ZHANG Ruizhe, XU Xiaoyang, GUO Ningjie, WU Shuhua. Correlation of LC3 and the recruitment of dendritic cell and the formation of TLS in colorectal cancer and its clinical significance [J]. China Oncology, 2023, 33(9): 818-828.
[15]	ZHOU Cong, HE Lina, CHENG Xiaojiao, HUANG Tinglei, TU Shuiping. Effect of RSPO3 on inhibiting the growth of colorectal cancer transplanted tumors and increasing NK cell infiltration in vivo [J]. China Oncology, 2023, 33(7): 664-672.